Sentences with phrase «libertyq global dividend»

«You've been able to find pockets of strength even this year,» says Bruce Cooper, who heads all equity teams at TD Asset Management and manages a global dividend fund.

I sold the following two funds: RBC Canadian Equity Income Class A RBC Global Dividend Growth Class A

The risk ratings of Franklin LibertyQT Global Dividend Index ETF (FLGD) and Franklin LibertyQT U.S. Equity Index ETF (FLUS) will be changed.

Effective July 31, 2015 Virtus Global Dividend Fund (PGUAX), a perfectly respectable fund with lots of global infrastructure exposure, becomes Virtus Global Infrastructure Fund.

Horizons Active Global Dividend (HAZ).

We do prefer stocks to government bonds, and within equities, we like global dividend - growth and quality stocks.

However, Horizons AlphaPro recently launched the actively managed Global Dividend ETF (HAZ), which is approximately 50 % in US stocks, 11 % Canadian and 39 % international.

The sectors covered by the active ETFs are Canadian Dividend, U.S. Dividend, Global Dividend, Preferred Shares and Crossover Bonds (those on the line between investment grade and high - yield).

In addition, we like the use of global dividend growth funds to diversify your retirement portfolio.

We listed several global dividend growth funds with expense ratios less than 1 %.

On October 1, Forward announced plans to reposition Forward Global Dividend Fund (FFLRX) as Forward Foreign Equity Fund on December 1.

PIMCO Balanced Income (PBIAX), PIMCO Global Dividend Fund (PQDAX), PIMCO International Dividend (PVIAX) and PIMCO U.S. Dividend (PVDAX) will go to their eternal rest on August 26, 2016.

RBC Strategic Global Dividend Leaders ETF seeks to provide unitholders with exposure to the performance of a diversified portfolio of high - quality global dividend - paying equity securities that will provide regular income and that have the potential for long - term capital growth.

It then «swaps» the returns of these equities for the returns of the global dividend portfolio, which is in fact held by National Bank.

If you prefer to not invest in individual dividend growth stocks, you can build a dividend portfolio through global dividend growth funds.

If you are looking for international dividend exposure, look at global dividend growth funds to diversify your portfolio.

Unless otherwise noted all information contained herein is that of the SPDR S&P Global Dividend ETF.

The Royce Fund's Board of Trustees recently approved a plan of liquidation for Royce Select Fund II (RSFDX), Royce Enterprise Select Fund (RMISX), Royce SMid - Cap Value Fund (RMVSX), Royce Partners Fund (RPTRX) and Royce Global Dividend Value Fund (RGVDX).

One of the older CEFs out there, the Wells Fargo Global Dividend Opportunity Fund has established a track record.

An analysis of global dividend policies attributed the rationale for companies to pay and raise their dividends to many factors, including communicating information, so - called «agency costs,» tax policy and a company's maturation.

Effective July 31, 2013, Epoch Investment Partners, Inc. became the portfolio adviser for the Epoch Global Shareholder Yield Fund (formerly TD Global Dividend Fund).

Now advisors can help clients choose from more than 30 broad - based international and global dividend - oriented ETFs, as well as a plethora of single - country dividend funds.

The LibertyQ Global Equity Index, LibertyQ Global Dividend Index, LibertyQ Emerging Markets Index and LibertyQ International Equity Hedged Index are owned and calculated by MSCI and are based on the MSCI ACWI Index, the MSCI ACWI ex REITs Index, the MSCI Emerging Markets Index, and the MSCI EAFE Index, respectively, and aim to reflect the performance of a Franklin Templeton strategy.

The index for Franklin LibertyQ Global Dividend ETF was constructed using proprietary dividend and quality screens, which account for not only long - term dividend sustainability and growth, but also for underlying balance sheet strength:

Global dividends from oil companies plunged 20 % last year.

Total global dividends actually declined slightly from 2014, notes the Henderson study, mainly because of the strength of the U.S. dollar.

Henderson projects that global dividends will increase to $ 1.17 trillion this year.

Here is a list of global dividend growth funds to choose from and their corresponding expense ratios:

For February, my stock buy was 80 shares of Virtus Global Dividend & Income Fund Inc (NYSE: ZTR) at $ 11.38 per share.

Here is a strong list of ETFs that offer global dividend growth.

I would not own a global dividend growth fund with those two stocks (BP and VOD) included in the top holdings.

There are plenty of high - quality international dividend growth stocks that you can invest in without owning a global dividend growth fund.

Schroder ISF Global Dividend Maximiser provides exposure to global opportunities, investing in a portfolio of carefully selected company shares from around the world.

There are a number of global dividend growth funds that have low expense ratios and have increased dividends over the past few years.

Global dividend growth faces two major headwinds in 2018 which could disrupt the otherwise - supportive backdrop for income, according to Martin Currie's Global Equity Income manager Mark Whitehead.»

A global dividend growth fund can help you diversify.

I like to complement great dividend growth stocks with one global dividend growth fund to ensure I'm diversified geographically.

First, I added 100 shares (at $ 11.75 each) of Virtus Global Dividend & Income Fund (NYSE: ZTR) to my dividend investing portfolio for a total of 300 shares of ZTR.

12/29/2017 (EVG, ETG) Eaton Vance Short Duration Income Fund (EVG), Eaton Vance Tax - Advantaged Global Dividend Income Fund (ETG)

01/31/2018 (EVG, ETG, EIM) Eaton Vance Short Duration Diversified Income Fund (EVG), Eaton Vance Tax - Advantaged Global Dividend Income Fund (ETG), Municipal Bond Fund (EIM)

The investment seeks to performance before the fees and expenses, of an equity index called the S&P Global Dividend Opportunities Index.

Not exact matches

Add in an average 3 % dividend, plus more global growth, and it may even break double digits.

All dividend stocks risk a hit to earnings from interest rates in the short term, says Rich Peterson, a senior director at S&P Global Market Intelligence.

Frank Holmes, CEO and chief investment officer with U.S. Global Investors, likes to see dividend payouts because it forces companies to be more prudent with their cash.

Global Construction Services has continued to withhold declaring a dividend despite reporting a 7.1 per cent rise in net profit to $ 8.7 million for the 2015 financial year, but says it hopes to deliver a payout next year.

There's another reason why markets will make people money in 2012, says Srikanth Iyer, head of global systematic investments for Toronto's Guardian Capital Group: dividend payouts are set to climb.

And while the industry is seeing some dividend increases, cash is increasingly the currency of choice for acquisitions, as equity multiples have been crushed by global macroeconomic trends.

That's according to Donald Sheppard, a guy with no college degree whose advertising agency was acquired by a global player in the space in 1999 (he discusses his journey to success in his book The Dividends of Decency).

But instead of distributing these profits back to shareholders in the form of dividends and share buybacks, many have chosen to retain sizable cash cushions to ensure future access to capital amid a shaky global banking system.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).